Which has stronger earnings and valuation, VTRS or PFE?

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viatris $14.30B 1.31 -$3.51B -$0.26 N/A Pfizer $62.58B 2.38 $7.77B $1.31 19.97

Is VTRS or PFE more profitable?

Pfizer has a net margin of 11.83% compared to Viatris' net margin of -2.04%. Pfizer's return on equity of 19.44% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Pfizer 11.83% 19.44% 8.41%

Does the media refer more to VTRS or PFE?

In the previous week, Pfizer had 57 more articles in the media than Viatris. MarketBeat recorded 60 mentions for Pfizer and 3 mentions for Viatris. Pfizer's average media sentiment score of 0.97 beat Viatris' score of 0.93 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 38 Very Positive mention(s) 8 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive

Do analysts rate VTRS or TAK?

Viatris presently has a consensus price target of $16.43, indicating a potential upside of 1.98%. Given Viatris' higher probable upside, research analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, VTRS or ARGX?

argenex has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viatris $14.30B 1.31 -$3.51B -$0.26 N/A argenex $4.25B 12.28 $1.29B $22.46 37.33

Is VTRS or ARGX more profitable?

argenex has a net margin of 31.31% compared to Viatris' net margin of -2.04%. argenex's return on equity of 33.28% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% argenex 31.31% 33.28% 28.16%

Does the media favor VTRS or ARGX?

In the previous week, argenex had 2 more articles in the media than Viatris. MarketBeat recorded 5 mentions for argenex and 3 mentions for Viatris. Viatris' average media sentiment score of 0.93 beat argenex's score of 0.38 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VTRS or TEVA?

In the previous week, Teva Pharmaceutical Industries had 6 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Teva Pharmaceutical Industries and 3 mentions for Viatris. Teva Pharmaceutical Industries' average media sentiment score of 1.38 beat Viatris' score of 0.93 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ONC or VTRS more profitable?

BeOne Medicines has a net margin of 8.94% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% Viatris -2.04% 19.04% 7.62%

Does the media favor ONC or VTRS?

In the previous week, BeOne Medicines had 5 more articles in the media than Viatris. MarketBeat recorded 8 mentions for BeOne Medicines and 3 mentions for Viatris. Viatris' average media sentiment score of 0.93 beat BeOne Medicines' score of -0.26 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viatris (VTRS) Competitors

$16.11 -0.18 (-1.10%)

Closing price 04:00 PM Eastern

Extended Trading

$16.02 -0.09 (-0.59%)

As of 06:16 PM Eastern

Compare

VTRS vs. PFE, TAK, ARGX, TEVA, and ONC

Should you buy Viatris stock or one of its competitors? MarketBeat compares Viatris with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viatris include Pfizer (PFE), Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). These companies are all part of the "medical" sector.

How does Viatris compare to Pfizer?

Viatris (NASDAQ:VTRS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 0.6% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Viatris presently has a consensus target price of $16.43, indicating a potential upside of 1.98%. Pfizer has a consensus target price of $28.61, indicating a potential upside of 9.39%. Given Pfizer's higher possible upside, analysts clearly believe Pfizer is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Pfizer	3 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.19

Pfizer has a net margin of 11.83% compared to Viatris' net margin of -2.04%. Pfizer's return on equity of 19.44% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Pfizer	11.83%	19.44%	8.41%

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.31	-$3.51B	-$0.26	N/A
Pfizer	$62.58B	2.38	$7.77B	$1.31	19.97

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 3.0%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.6%. Viatris pays out -184.6% of its earnings in the form of a dividend. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Pfizer had 57 more articles in the media than Viatris. MarketBeat recorded 60 mentions for Pfizer and 3 mentions for Viatris. Pfizer's average media sentiment score of 0.97 beat Viatris' score of 0.93 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	38 Very Positive mention(s)	8 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Positive

Viatris has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Summary

Pfizer beats Viatris on 16 of the 20 factors compared between the two stocks.

How does Viatris compare to Takeda Pharmaceutical?

Viatris (NASDAQ:VTRS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Viatris had 3 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 3 mentions for Viatris and 0 mentions for Takeda Pharmaceutical. Viatris' average media sentiment score of 0.93 beat Takeda Pharmaceutical's score of -0.08 indicating that Viatris is being referred to more favorably in the media.

Company	Overall Sentiment
Viatris	Positive
Takeda Pharmaceutical	Neutral

Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.31	-$3.51B	-$0.26	N/A
Takeda Pharmaceutical	$28.32B	1.82	$1.27B	$0.39	41.45

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 3.0%. Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.1%. Viatris pays out -184.6% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 128.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Viatris has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 4.31% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

Viatris presently has a consensus price target of $16.43, indicating a potential upside of 1.98%. Given Viatris' higher probable upside, research analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Viatris beats Takeda Pharmaceutical on 10 of the 18 factors compared between the two stocks.

How does Viatris compare to argenex?

Viatris (NASDAQ:VTRS) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

argenex has a net margin of 31.31% compared to Viatris' net margin of -2.04%. argenex's return on equity of 33.28% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
argenex	31.31%	33.28%	28.16%

Viatris currently has a consensus target price of $16.43, indicating a potential upside of 1.98%. argenex has a consensus target price of $1,017.78, indicating a potential upside of 21.38%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, argenex had 2 more articles in the media than Viatris. MarketBeat recorded 5 mentions for argenex and 3 mentions for Viatris. Viatris' average media sentiment score of 0.93 beat argenex's score of 0.38 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.9% of Viatris shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Viatris has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

argenex has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.31	-$3.51B	-$0.26	N/A
argenex	$4.25B	12.28	$1.29B	$22.46	37.33

Summary

argenex beats Viatris on 13 of the 17 factors compared between the two stocks.

How does Viatris compare to Teva Pharmaceutical Industries?

Viatris (NASDAQ:VTRS) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Viatris' net margin of -2.04%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

79.9% of Viatris shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Viatris currently has a consensus price target of $16.43, suggesting a potential upside of 1.98%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 20.94%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Teva Pharmaceutical Industries had 6 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Teva Pharmaceutical Industries and 3 mentions for Viatris. Teva Pharmaceutical Industries' average media sentiment score of 1.38 beat Viatris' score of 0.93 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.31	-$3.51B	-$0.26	N/A
Teva Pharmaceutical Industries	$17.26B	2.30	$1.41B	$1.33	25.97

Viatris has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Viatris on 14 of the 16 factors compared between the two stocks.

How does Viatris compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

BeOne Medicines has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.97	$286.93M	$4.47	65.01
Viatris	$14.30B	1.31	-$3.51B	-$0.26	N/A

BeOne Medicines has a net margin of 8.94% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Viatris	-2.04%	19.04%	7.62%

BeOne Medicines has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Viatris has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

BeOne Medicines currently has a consensus target price of $389.15, suggesting a potential upside of 33.92%. Viatris has a consensus target price of $16.43, suggesting a potential upside of 1.98%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, BeOne Medicines had 5 more articles in the media than Viatris. MarketBeat recorded 8 mentions for BeOne Medicines and 3 mentions for Viatris. Viatris' average media sentiment score of 0.93 beat BeOne Medicines' score of -0.26 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BeOne Medicines beats Viatris on 11 of the 17 factors compared between the two stocks.

Get Viatris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTRS vs. The Competition

Export

Metric	Viatris	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.76B	$8.63B	$6.44B	$12.57B
Dividend Yield	2.95%	2.99%	2.75%	5.25%
P/E Ratio	-61.96	22.33	21.55	26.15
Price / Sales	1.31	25.70	618.79	118.48
Price / Cash	2.20	85.92	43.13	56.80
Price / Book	1.28	6.00	10.53	7.26
Net Income	-$3.51B	$186.05M	$3.56B	$337.24M
7 Day Performance	-2.13%	5.57%	3.21%	3.91%
1 Month Performance	8.70%	13.25%	4.59%	5.84%
1 Year Performance	87.54%	7.07%	37.82%	38.37%

Viatris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTRS Viatris	2.9327 of 5 stars	$16.11 -1.1%	$16.43 +2.0%	+89.4%	$18.76B	$14.30B	N/A	30,000
PFE Pfizer	3.8894 of 5 stars	$25.31 -0.1%	$28.84 +14.0%	+11.1%	$144.37B	$62.58B	19.32	75,000	Trending News Analyst Forecast
TAK Takeda Pharmaceutical	2.6189 of 5 stars	$16.58 -0.2%	N/A	+10.1%	$52.86B	$28.32B	42.50	47,455
ARGX argenex	4.0449 of 5 stars	$776.26 -2.9%	$1,017.78 +31.1%	+41.5%	$49.46B	$4.25B	34.56	1,863
TEVA Teva Pharmaceutical Industries	4.8417 of 5 stars	$34.08 -0.6%	$41.78 +22.6%	+95.2%	$39.43B	$17.26B	25.62	33,950

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTRS) was last updated on 5/28/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viatris (VTRS) Competitors

VTRS vs. PFE, TAK, ARGX, TEVA, and ONC

How does Viatris compare to Pfizer?

Summary

How does Viatris compare to Takeda Pharmaceutical?

Summary

How does Viatris compare to argenex?

Summary

How does Viatris compare to Teva Pharmaceutical Industries?

Summary

How does Viatris compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS vs. The Competition

Viatris Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viatris (VTRS) Competitors

VTRS vs. PFE, TAK, ARGX, TEVA, and ONC

How does Viatris compare to Pfizer?

Do insiders and institutionals have more ownership in VTRS or PFE?

Do analysts recommend VTRS or PFE?

Is VTRS or PFE more profitable?

Which has stronger earnings and valuation, VTRS or PFE?

Is VTRS or PFE a better dividend stock?

Does the media refer more to VTRS or PFE?

Which has more risk & volatility, VTRS or PFE?

Summary

How does Viatris compare to Takeda Pharmaceutical?

Does the media favor VTRS or TAK?

Which has stronger earnings & valuation, VTRS or TAK?

Is VTRS or TAK a better dividend stock?

Which has more risk and volatility, VTRS or TAK?

Do institutionals & insiders have more ownership in VTRS or TAK?

Is VTRS or TAK more profitable?

Do analysts rate VTRS or TAK?

Summary

How does Viatris compare to argenex?

Is VTRS or ARGX more profitable?

Do analysts prefer VTRS or ARGX?

Does the media favor VTRS or ARGX?

Do insiders and institutionals hold more shares of VTRS or ARGX?

Which has more volatility & risk, VTRS or ARGX?

Which has better valuation and earnings, VTRS or ARGX?

Summary

How does Viatris compare to Teva Pharmaceutical Industries?

Is VTRS or TEVA more profitable?

Do institutionals and insiders hold more shares of VTRS or TEVA?

Do analysts prefer VTRS or TEVA?

Does the media prefer VTRS or TEVA?

Which has better valuation & earnings, VTRS or TEVA?

Which has more risk & volatility, VTRS or TEVA?

Summary

How does Viatris compare to BeOne Medicines?

Which has better earnings and valuation, ONC or VTRS?

Is ONC or VTRS more profitable?

Which has more risk & volatility, ONC or VTRS?

Do analysts recommend ONC or VTRS?

Do insiders & institutionals believe in ONC or VTRS?

Does the media favor ONC or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS vs. The Competition

Viatris Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools